Results of Mass Switch From Latanoprost to Travoprost

NCT00347126 | Completed

• 1 other identifier: R463/12/2006
• Study Type: observational
• Target: 372
• Locations: 1 country
• Sites: 1

Brief Summary

Prostaglandin analogs are a leading class of glaucoma drugs with a proven safety and efficacy for controlling IOP. They include latanoprost, bimatoprost, travoprost and unoprostone. Recently, the Singapore National Eye Center (SNEC) awarded a tender for prostaglandin analogues to Alcon, the manufacturer of travoprost. Since then, all subsidized patients previously treated with latanoprost were systematically switched to travoprost and this process will continue for the rest of this year. In this study, we propose to prospectively study the efficacy and safety of switching from latanoprost to travoprost in a large series of glaucoma patients at SNEC. A total of 372 consecutive patients being switched from latanoprost to travoprost will be followed up for 12 weeks following the switch. In addition to intraocular pressure, the safety and tolerability (with particular emphasis on hyperemia) of travoprost will be examined.

Conditions

Glaucoma

Keywords

Glaucoma; Latanoprost; Travoprost; Intraocular pressure; Hyperemia

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients on treatment with latanoprost who are switched to travoprost therapy

You may qualify if:

• Patients on treatment with latanoprost for at least 12 weeks; patients who are on additional beta-blockers topically will also be eligible.
• Written informed consent. -

You may not qualify if:

• Patients on 3 or more topical medications.
• Recorded history of intolerance to travoprost.
• Recorded history of inefficacy of travoprost in controlling IOP.
• Patients on any additional topical medication other than beta-blockers.
• History of non-compliance.
• Involvement in any other concomitant study. -

Sponsors & Collaborators

• Singapore National Eye Centre: lead

Study Sites (1)

Singapore National Eye Centre

Singapore, 168751, Singapore

Location

MeSH Terms

Conditions

Glaucoma; Hyperemia

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Tin Aung, FRCS, PhD

  Singapore National Eye Centre

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: June 30, 2006
• First Posted: July 4, 2006
• Study Start: April 1, 2006
• Study Completion: April 1, 2008
• Last Updated: May 12, 2010

Record last verified: 2010-05

Locations

SG (1)